Accelerating DoD’s Fielding of Prototypes for
Medical Countermeasures

The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.

WHO CAN JOIN?

Companies that are part of the US Industrial base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects.

• Traditional Contractors
• Non-Traditionals (Companies that don’t typically participate in Federal R&D)
• Academia
• Non-Profit/Not-For-Profit Research Institutions

Prophylaxis, pretreatment, and post-exposure prophylaxis

Systems and devices to identify CBRN agents and assist in making medical decisions

Therapeutics for post-exposure and post-symptomatic

MCDC research and prototype work is executed by project teams from a broad-based industry/academia collaboration.

Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense